2 recruiting, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 6 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 2, Terminated 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Sasanlimab: new trials by email Literature Review of Sasanlimab trials Research Report on Sasanlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma Sasanlimab, Palbociclib, Axitinib - Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer | Phase 2 | Recruiting | Stephanie Berg | 25 | 2025-11-24 | 2026-08-20 |
| Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor Sasanlimab, non-ablative radiotherapy, [89Zr]Zr-crefmirlimab berdoxam - NSCLC | Phase 2 / Phase 3 | Not yet recruiting | Radboud University Medical Center | 20 | 2025-02-01 | 2024-11-29 |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) Sasanlimab, Palbocicilib - Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc) | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 100 | 2024-04-24 | 2026-10-16 |
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) NKT2152, palbociclib, sasanlimab - ccRCC, Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | NiKang Therapeutics, Inc. | 18 | 2023-07-28 | 2025-11-12 |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion - Urothelial Carcinoma Bladder | Phase 2 | Active not recruiting | The Methodist Hospital Research Institute | 33 | 2022-02-15 | 2025-10-24 |
| Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) Sasanlimab Prefilled syringe, Encorafenib, Binimetinib - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Terminated | Pfizer | 34 | 2020-11-10 | 2026-01-09 |
Carcinoma, Renal Cell (3) · Kidney Neoplasms (3) · Urologic Diseases (2) · Urologic Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Kidney Diseases (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Urinary Bladder Diseases (1) · Urinary Bladder Neoplasms (1)
National Cancer Institute (NCI) (1) · NiKang Therapeutics, Inc. (1) · Pfizer (1) · Radboud University Medical Center (1) · Stephanie Berg (1) · The Methodist Hospital Research Institute (1)
United States (5) · Australia (1) · Belgium (1) · Germany (1) · Netherlands (1) · Taiwan (1)
Dominik Sonanini, Dr. (1) · Raj Satkunasivam, MD (1) · Ramaprasad Srinivasan, M.D. (1) · Stephanie Berg, DO (1)